Your SlideShare is downloading. ×
SYMPLICITY HTN-2 trial - Summary & Results
SYMPLICITY HTN-2 trial - Summary & Results
SYMPLICITY HTN-2 trial - Summary & Results
SYMPLICITY HTN-2 trial - Summary & Results
SYMPLICITY HTN-2 trial - Summary & Results
Upcoming SlideShare
Loading in...5

Thanks for flagging this SlideShare!

Oops! An error has occurred.

Saving this for later? Get the SlideShare app to save on your phone or tablet. Read anywhere, anytime – even offline.
Text the download link to your phone
Standard text messaging rates apply

SYMPLICITY HTN-2 trial - Summary & Results


Published on …

A Randomized study on Renal Denervation in Patients With Uncontrolled Hypertension (SYMPLICITY HTN-2)

Published in: Health & Medicine
1 Like
  • Be the first to comment

No Downloads
Total Views
On Slideshare
From Embeds
Number of Embeds
Embeds 0
No embeds

Report content
Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

No notes for slide


  • 1. SYMPLICITY HTN-2 (Renal Denervation inPatients With Uncontrolled Hypertension)
  • 2. SYMPLICITY HTN-2 (Renal Denervation inPatients With Uncontrolled Hypertension)MD Esler (Baker IDI Heart and Diabetes Institute, Melbourne, Australia)American Heart Association 2010 Scientific Sessions• Background: Renal sympathetic efferent and afferent nerves are crucial for the initiation and maintenance of systemic hypertension Denervation of the renal sympathetic nerve to reduce BP has been attempted, unsuccessfully, by surgical means years ago• Population and treatment: 106 patients with resistant hypertension (SBP >160 mm Hg, or >150 mm Hg for those with type 2 diabetes, taking ≥ three antihypertensive drugs) Randomized 1:1 to renal denervation + previous treatment (n=52) or previous treatment alone (n=51)• Primary outcome: BP reduction at six months
  • 3. SYMPLICITY HTN-2: Results• Average office-based BP in the renal-denervation group was reduced 32/12 mm Hg (average baseline 178/96 mm Hg) six months after the ablation• Between-group differences in BP at six months were 33/11 mm Hg (p<0.0001)• Of the patients in the ablation arm, 84% had a 10-mm-Hg or greater drop in SBP vs 35% of controls (p<0.0001)• There did not appear to be any adverse events: Imaging of renal arteries for damage showed no evidence of renal artery stenosis or aneurysmal dilatation during the six-month follow-up There were no changes in renal function, even in those with mild to moderate renal failure
  • 4. SYMPLICITY HTN-2: Commentary*"This has the potential for really revolutionizing the way we treat resistanthypertension, which is an enormous clinical need." - Dr Suzanne Oparil"Ive never seen BP falls as big as this from any other treatment process, whichmakes the possibility of cure realistic; it might be within reach." - Dr Murray D Esler"My only reservation about the study is that they have not compared thedenervation with the most effective add-on drug in patients with resistanthypertension, which is spironolactone." - Dr Peter Sever*All comments from A revolutionary road for resistant hypertension? Renal denervation in SymplicityHTN-2 (
  • 5. Become a member of Become a fan on Facebook: Follow us on Twitter: is the leading online source of independent cardiology news.We are the top provider of news and opinions for over 100 000 physicians.